| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 937 | 2018 |
| BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ... Journal of Clinical Oncology 35 (13), 1437, 2017 | 471 | 2017 |
| Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia MR Grever, O Abdel-Wahab, LA Andritsos, V Banerji, J Barrientos, ... Blood, The Journal of the American Society of Hematology 129 (5), 553-560, 2017 | 255 | 2017 |
| Expression and prognostic impact of lncRNAs in acute myeloid leukemia R Garzon, S Volinia, D Papaioannou, D Nicolet, J Kohlschmidt, PS Yan, ... Proceedings of the National Academy of Sciences 111 (52), 18679-18684, 2014 | 238 | 2014 |
| BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor HG Ozer, D El-Gamal, B Powell, ZA Hing, JS Blachly, B Harrington, ... Cancer discovery 8 (4), 458-477, 2018 | 116 | 2018 |
| Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma JS Blachly, RA Baiocchi British journal of haematology 167 (1), 19-32, 2014 | 100 | 2014 |
| Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies AK Eisfeld, J Kohlschmidt, K Mrózek, JS Blachly, CJ Walker, D Nicolet, ... Leukemia 32 (6), 1338-1348, 2018 | 96 | 2018 |
| The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia AK Eisfeld, K Mrózek, J Kohlschmidt, D Nicolet, S Orwick, CJ Walker, ... Leukemia 31 (10), 2211-2218, 2017 | 88 | 2017 |
| Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged< 60 years AK Eisfeld, J Kohlschmidt, A Mims, D Nicolet, CJ Walker, JS Blachly, ... Leukemia 34 (12), 3215-3227, 2020 | 85 | 2020 |
| Resistance to acalabrutinib in CLL is mediated primarily by BTK mutations J Woyach, Y Huang, K Rogers, SA Bhat, MR Grever, A Lozanski, ... Blood 134, 504, 2019 | 82 | 2019 |
| Emerging drug profile: cyclin-dependent kinase inhibitors JS Blachly, JC Byrd Leukemia & lymphoma 54 (10), 2133-2143, 2013 | 80 | 2013 |
| Acalabrutinib plus obinutuzumab in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia JA Woyach, JS Blachly, KA Rogers, SA Bhat, M Jianfar, G Lozanski, ... Cancer discovery 10 (3), 394-405, 2020 | 76 | 2020 |
| Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A M Bill, K Mrózek, J Kohlschmidt, AK Eisfeld, CJ Walker, D Nicolet, ... Proceedings of the National Academy of Sciences 117 (42), 26340-26346, 2020 | 70 | 2020 |
| Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinically K Mrózek, AK Eisfeld, J Kohlschmidt, AJ Carroll, CJ Walker, D Nicolet, ... Leukemia 33 (7), 1620-1634, 2019 | 69 | 2019 |
| EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, LA Sutton, ... Leukemia 31 (7), 1547-1554, 2017 | 69 | 2017 |
| Quality control for RNA-Seq (QuaCRS): an integrated quality control pipeline KW Kroll, NE Mokaram, AR Pelletier, DE Frankhouser, MS Westphal, ... Cancer informatics 13, CIN. S14022, 2014 | 63 | 2014 |
| Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia B Bhatnagar, AK Eisfeld, D Nicolet, K Mrózek, JS Blachly, S Orwick, ... British journal of haematology 175 (2), 226-236, 2016 | 62 | 2016 |
| HDAC inhibition induces microRNA-182, which targets RAD51 and impairs HR repair to sensitize cells to sapacitabine in acute myelogenous leukemia TH Lai, B Ewald, A Zecevic, C Liu, M Sulda, D Papaioannou, R Garzon, ... Clinical cancer research 22 (14), 3537-3549, 2016 | 62 | 2016 |
| Phase 2 study of ibrutinib in classic and variant hairy cell leukemia KA Rogers, LA Andritsos, L Wei, EM McLaughlin, AS Ruppert, ... Blood, The Journal of the American Society of Hematology 137 (25), 3473-3483, 2021 | 56 | 2021 |
| PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL D El-Gamal, K Williams, TD LaFollette, M Cannon, JS Blachly, Y Zhong, ... Blood, The Journal of the American Society of Hematology 124 (9), 1481-1491, 2014 | 55 | 2014 |
john C. ByrdDistinguished University Professor, The Ohio State UniversityVerified email at osumc.edu
